[144] BioNTech SE American Depositary Share SEC Filing
Form 144 filed for BioNTech SE (BNTX) reporting a proposed sale of 185,001 American Depositary Shares (ADS) representing ordinary shares. The broker listed is Berenberg Capital Markets LLC with an approximate sale date of 08/15/2025 on Nasdaq Global Select. The aggregate market value of the proposed sale is reported as $20,849,612.70 and the number of shares outstanding is listed as 240,398,724. The securities were acquired on 11/21/2022 through a stock option exercise from BioNTech SE. The filer reports no securities sold in the past three months and includes the standard certification that the seller is not aware of undisclosed material adverse information.
Deposito del Modulo 144 per BioNTech SE (BNTX) che segnala una proposta di vendita di 185.001 American Depositary Shares (ADS) rappresentanti azioni ordinarie. Il broker indicato 猫 Berenberg Capital Markets LLC con data approssimativa di vendita il 15/08/2025 sul Nasdaq Global Select. Il valore di mercato complessivo della vendita proposta 猫 riportato in $20.849.612,70 e il numero di azioni in circolazione 猫 240.398.724. I titoli sono stati acquisiti il 21/11/2022 tramite un esercizio di opzione su azioni da BioNTech SE. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi e include la certificazione standard che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate.
Formulario 144 presentado para BioNTech SE (BNTX) que informa una propuesta de venta de 185.001 American Depositary Shares (ADS) que representan acciones ordinarias. El corredor indicado es Berenberg Capital Markets LLC con fecha aproximada de venta el 15/08/2025 en el Nasdaq Global Select. El valor de mercado agregado de la venta propuesta se informa como $20.849.612,70 y el n煤mero de acciones en circulaci贸n se indica como 240.398.724. Los valores fueron adquiridos el 21/11/2022 mediante un ejercicio de opci贸n sobre acciones de BioNTech SE. El presentador declara no haber vendido valores en los 煤ltimos tres meses e incluye la certificaci贸n est谩ndar de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada.
BioNTech SE (BNTX)鞐� 雽�頃� Form 144 鞝滌稖搿� 氤错喌欤茧ゼ 雽�響滍晿電� 185,001欤� American Depositary Shares(ADS)鞚� 毵り皝 鞓堨爼鞚� 氤搓碃霅橃棃鞀惦媹雼�. 歆�鞝� 欷戧皽鞚胳潃 Berenberg Capital Markets LLC鞚措┌ 鞓堨儊 毵り皝 鞓堨爼鞚检潃 2025-08-15搿� Nasdaq Global Select鞐� 靸侅灔霅橃柎 鞛堨姷雼堧嫟. 鞓堨爼 毵り皝鞚� 齑� 鞁滌灔 臧�旃橂姅 $20,849,612.70搿� 氤搓碃霅橃棃瓿� 氚滍枆 欤检嫕 靾橂姅 240,398,724欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 歃濌秾鞚� 2022-11-21鞐� BioNTech SE搿滊秬韯� 鞀ろ啞鞓奠厴 頄夓偓毳� 韱淀暣 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖鞚胳潃 瓿缄卑 3臧滌洈臧� 歃濌秾鞚� 毵り皝頃橃 鞎婌晿鞚岇潉 氤搓碃頃橁碃, 毵る弰鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑氍胳潉 韽暔頃橁碃 鞛堨姷雼堧嫟.
Formulaire 144 d茅pos茅 pour BioNTech SE (BNTX) signalant une proposition de vente de 185 001 American Depositary Shares (ADS) repr茅sentant des actions ordinaires. Le courtier indiqu茅 est Berenberg Capital Markets LLC avec une date de vente approximative au 15/08/2025 sur le Nasdaq Global Select. La valeur de march茅 globale de la vente propos茅e est indiqu茅e 脿 20 849 612,70 $ et le nombre d'actions en circulation est mentionn茅 comme 240 398 724. Les titres ont 茅t茅 acquis le 21/11/2022 par un exercice d'option d'achat d'actions de BioNTech SE. Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois et inclut la certification standard pr茅cisant que le vendeur n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Formular 144 eingereicht f眉r BioNTech SE (BNTX), das einen geplanten Verkauf von 185.001 American Depositary Shares (ADS) darlegt, die Stammaktien repr盲sentieren. Der genannte Broker ist Berenberg Capital Markets LLC mit einem ungef盲hren Verkaufsdatum am 15.08.2025 an der Nasdaq Global Select. Der aggregierte Marktwert des geplanten Verkaufs wird mit $20.849.612,70 angegeben und die ausstehenden Aktien werden mit 240.398.724 aufgef眉hrt. Die Wertpapiere wurden am 21.11.2022 durch Aus眉bung einer Aktienoption von BioNTech SE erworben. Der Einreicher meldet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und f眉gt die 眉bliche Best盲tigung bei, dass der Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen kenne.
- Regulatory compliance: The filer provided required Form 144 details including broker, share count, and aggregate market value.
- Transparency on acquisition: The securities were identified as acquired by stock option exercise on 11/21/2022, clarifying origin of the shares.
- Insider sale proposed: The notice indicates an insider intends to sell 185,001 ADSs, which may increase share supply.
- Limited disclosure on intentions: The filing does not indicate whether the sale is under a 10b5-1 trading plan or provide pricing details beyond aggregate market value.
Insights
TL;DR Insider-originated ADS sale notice for 185,001 shares valued at about $20.85M; routine regulatory disclosure.
The Form 144 documents a proposed sale of 185,001 BioNTech ADSs acquired by stock option exercise on 11/21/2022. The notice names Berenberg Capital Markets as the broker and targets an approximate sale date of 08/15/2025 on Nasdaq Global Select. No sales in the prior three months are reported. As a market professional, I view this as a standard insider sale filing that provides transparency on potential share supply entering the market. The filing does not include pricing details beyond aggregate market value nor any explanation of intent or trading plan.
TL;DR Form 144 reflects required compliance; signals an insider disposition but contains no evidence of undisclosed material information.
The filer declares the securities were acquired via stock option exercise from BioNTech SE and affirms no known undisclosed material adverse information. The filing meets procedural requirements by identifying the broker, share count, aggregate value, and proposed sale date. It does not state whether the sale is part of a Rule 10b5-1 plan or provide additional governance context. From a governance standpoint, the filing is a routine disclosure enabling market participants to monitor insider activity.
Deposito del Modulo 144 per BioNTech SE (BNTX) che segnala una proposta di vendita di 185.001 American Depositary Shares (ADS) rappresentanti azioni ordinarie. Il broker indicato 猫 Berenberg Capital Markets LLC con data approssimativa di vendita il 15/08/2025 sul Nasdaq Global Select. Il valore di mercato complessivo della vendita proposta 猫 riportato in $20.849.612,70 e il numero di azioni in circolazione 猫 240.398.724. I titoli sono stati acquisiti il 21/11/2022 tramite un esercizio di opzione su azioni da BioNTech SE. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi e include la certificazione standard che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate.
Formulario 144 presentado para BioNTech SE (BNTX) que informa una propuesta de venta de 185.001 American Depositary Shares (ADS) que representan acciones ordinarias. El corredor indicado es Berenberg Capital Markets LLC con fecha aproximada de venta el 15/08/2025 en el Nasdaq Global Select. El valor de mercado agregado de la venta propuesta se informa como $20.849.612,70 y el n煤mero de acciones en circulaci贸n se indica como 240.398.724. Los valores fueron adquiridos el 21/11/2022 mediante un ejercicio de opci贸n sobre acciones de BioNTech SE. El presentador declara no haber vendido valores en los 煤ltimos tres meses e incluye la certificaci贸n est谩ndar de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada.
BioNTech SE (BNTX)鞐� 雽�頃� Form 144 鞝滌稖搿� 氤错喌欤茧ゼ 雽�響滍晿電� 185,001欤� American Depositary Shares(ADS)鞚� 毵り皝 鞓堨爼鞚� 氤搓碃霅橃棃鞀惦媹雼�. 歆�鞝� 欷戧皽鞚胳潃 Berenberg Capital Markets LLC鞚措┌ 鞓堨儊 毵り皝 鞓堨爼鞚检潃 2025-08-15搿� Nasdaq Global Select鞐� 靸侅灔霅橃柎 鞛堨姷雼堧嫟. 鞓堨爼 毵り皝鞚� 齑� 鞁滌灔 臧�旃橂姅 $20,849,612.70搿� 氤搓碃霅橃棃瓿� 氚滍枆 欤检嫕 靾橂姅 240,398,724欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 歃濌秾鞚� 2022-11-21鞐� BioNTech SE搿滊秬韯� 鞀ろ啞鞓奠厴 頄夓偓毳� 韱淀暣 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖鞚胳潃 瓿缄卑 3臧滌洈臧� 歃濌秾鞚� 毵り皝頃橃 鞎婌晿鞚岇潉 氤搓碃頃橁碃, 毵る弰鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑氍胳潉 韽暔頃橁碃 鞛堨姷雼堧嫟.
Formulaire 144 d茅pos茅 pour BioNTech SE (BNTX) signalant une proposition de vente de 185 001 American Depositary Shares (ADS) repr茅sentant des actions ordinaires. Le courtier indiqu茅 est Berenberg Capital Markets LLC avec une date de vente approximative au 15/08/2025 sur le Nasdaq Global Select. La valeur de march茅 globale de la vente propos茅e est indiqu茅e 脿 20 849 612,70 $ et le nombre d'actions en circulation est mentionn茅 comme 240 398 724. Les titres ont 茅t茅 acquis le 21/11/2022 par un exercice d'option d'achat d'actions de BioNTech SE. Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois et inclut la certification standard pr茅cisant que le vendeur n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Formular 144 eingereicht f眉r BioNTech SE (BNTX), das einen geplanten Verkauf von 185.001 American Depositary Shares (ADS) darlegt, die Stammaktien repr盲sentieren. Der genannte Broker ist Berenberg Capital Markets LLC mit einem ungef盲hren Verkaufsdatum am 15.08.2025 an der Nasdaq Global Select. Der aggregierte Marktwert des geplanten Verkaufs wird mit $20.849.612,70 angegeben und die ausstehenden Aktien werden mit 240.398.724 aufgef眉hrt. Die Wertpapiere wurden am 21.11.2022 durch Aus眉bung einer Aktienoption von BioNTech SE erworben. Der Einreicher meldet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und f眉gt die 眉bliche Best盲tigung bei, dass der Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen kenne.
FAQ
What does the Form 144 filed for BioNTech (BNTX) report?
When and how were the shares being sold by the filer acquired?
Does the Form 144 show any sales of BioNTech ADSs in the past three months?
Which broker is handling the proposed sale of BNTX ADSs?
What exchange is the proposed BioNTech sale expected to occur on?
